Tumor Treating Fields Therapy

Policy # 00391
Original Effective Date: 11/20/2013
Current Effective Date: 10/10/2022

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Stereotactic Radiosurgery and Stereotactic Body Radiotherapy is addressed separately in medical policy 00045.

Note: Intracavitary Balloon Catheter Brain Brachytherapy for Malignant Gliomas or Metastasis to the Brain is addressed separately in medical policy 00434.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider an initial 6 months of tumor treating fields (TTF) therapy to treat glioblastoma multiforme (GBM) as an adjunct to standard maintenance therapy with temozolomide in individuals with newly diagnosed GBM following initial treatment with surgery, radiotherapy, and/or chemotherapy to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility will be met for TTF therapy to treat GBM as an adjunct to standard maintenance therapy with temozolomide in individuals with newly diagnosed GBM following initial treatment with surgery, radiotherapy, and/or chemotherapy under the following conditions (ALL criteria must be met):

- Individuals ≥18 years of age; AND
- Supratentorial tumor following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy; AND
- Karnofsky Performance Status (KPS) score ≥70%; AND
- Individual understands device use, including the requirement for a shaved head, and is willing to use Optune for at least 18 hours a day.

**2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Based on review of available data, the Company may consider continuation of tumor treating fields (TTF) therapy to be eligible for coverage.**

**Patient Selection Criteria**
Coverage eligibility will be met for continuation of TTF therapy for 3 months if ALL of the following criteria are met:

- Evidence of no documented disease progression by magnetic resonance imaging (MRI) done at a minimum of every 2-4 months. This includes a completed MRI scan report submitted as part of any request for continuation; **AND**
- Karnofsky Performance Status (KPS) score of 70% or greater; **AND**
- Documentation that the individual has agreed to use Optune for at least 18 hours a day and has attempted to use it at least 75% of the time for 18 hours per day.

**When Services Are Considered Investigational**
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers tumor treating fields (TTF) therapy to be investigational* in all other conditions, including but not limited to the following situations:

- As an adjunct to standard medical therapy (e.g., bevacizumab, chemotherapy) for individuals with progressive or recurrent glioblastoma multiforme (GBM);
- As an alternative to standard medical therapy for patients with progressive or recurrent GBM;
- For brain metastases;
- For cancer in areas other than the brain.
- As an adjunct to standard medical therapy (pemetrexed and platinum-based chemotherapy) for individuals with malignant pleural mesothelioma

The use of tumor treating fields (TTF) therapy when patient selection criteria are not met is considered to be investigational.*
Tumor Treating Fields Therapy

Policy # 00391
Original Effective Date: 11/20/2013
Current Effective Date: 10/10/2022

Policy Guidelines
Progression was defined in the EF-14 trial (Stupp et al [2015, 2017]) according to the MacDonald criteria (tumor growth >25% compared with the smallest tumor area measured in the patient during the trial or appearance of 1 or more new tumors in the brain that are diagnosed radiologically as glioblastoma multiforme).

The U.S. Food and Drug Administration label includes the following notices:
- Individuals should use Optune for at least 18 hours a day to get the best response to treatment.
- Individuals should finish at least 4 full weeks of therapy to get the best response to treatment. Stopping treatment before 4 weeks lowers the chances of a response to treatment.

Background/Overview
Glioblastoma Multiforme
Glioblastomas, also known as glioblastoma multiforme (GBM), are the most common form of malignant primary brain tumor in adults. Glioblastomas are grade IV astrocytomas, a rapidly progressing and deadly type of glial cell tumor that is often resistant to standard medical therapy (eg, bevacizumab, chemotherapy). Together, anaplastic astrocytomas and glioblastomas comprise approximately 38% of all brain and central nervous system tumors. The peak incidence for GBM occurs between the ages of 45 and 70 years, with a median age at diagnosis of 64 years. Glioblastomas have the lowest survival rate of any central nervous system tumor; the 5-year survival rate and average length of survival is estimated at 6.8% and 12 to 18 months, respectively.

Treatment of Newly Diagnosed Glioblastoma Multiforme
The primary treatment for patients newly diagnosed with GBM is to resect the tumor to confirm a diagnosis while debulking the tumor to relieve symptoms of increased intracranial pressure or compression. If total resection is not feasible, subtotal resection and open biopsy are options. During surgery, some patients may undergo implantation of the tumor cavity with a carmustine (bis-chloroethyl nitrosourea) impregnated wafer. Due to the poor efficacy of local treatment, postsurgical treatment with adjuvant radiotherapy (RT), chemotherapy (typically temozolomide), or a combination of these 2 therapies is recommended. After adjuvant therapy, patients may undergo maintenance therapy with temozolomide. Maintenance temozolomide is given for 5 days of every 28-day cycle for 6 cycles. Response and overall survival rates with temozolomide are higher in patients who have O⁶-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Tumor Treating Fields Therapy

Policy # 00391
Original Effective Date: 11/20/2013
Current Effective Date: 10/10/2022

Prognostic factors for therapy success are age, histology, performance status or physical condition of the patient, and extent of resection. National Comprehensive Cancer Network recommendations include patient age and Karnofsky Performance Status score as important determinants of postsurgical treatment choice (see the Supplemental Information section). For patients with good performance status, the most aggressive treatment (standard RT plus temozolomide) is recommended. For patients with poor performance status, only single treatment cycles or even palliative or supportive care are recommended. Hypofractionated RT is indicated for patients with poor performance status because it is better tolerated, and more patients are able to complete RT.

Treatment of GBM is rarely curative, and tumors will recur in essentially all patients.

Treatment of Recurrent Glioblastoma Multiforme
When disease recurs, additional debulking surgery may be used if the recurrence is localized. Due to radiation tolerances, re-radiation options for patients with recurrent GBM who have previously received initial external-beam RT are limited. There is no standard adjunctive treatment for recurrent GBM. Treatment options for recurrent disease include various forms of systemic medications such as the antivascular endothelial growth factor drug bevacizumab, alkylating agents such as nitrosoureas (eg, lomustine, carmustine), or retreatment with temozolomide. Medical therapy is associated with side effects that include hematologic toxicity, headache, loss of appetite, nausea, vomiting, and fatigue. Response rates in recurrent disease are less than 10%, and the progression-free survival rate at 6 months is less than 20%. There is a need for new treatments that can improve survival in patients with recurrent GBM or reduce the side effects of treatment while retaining survival benefits.

Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive tumor that is associated with significant morbidity and mortality. It is associated with asbestos exposure and has a latency period of about 40 years after asbestos exposure. Recommendations for treatment are mainly chemotherapy as first line with pemetrexed plus platinum. Surgical cytoreduction is also recommended in selected patients with early-stage disease. Adjuvant radiation can be offered for patients who have resection of intervention tracts found to be histologically positive or for palliation of symptomatic patients.
Tumor Treating Fields Therapy

Policy #  00391
Original Effective Date:  11/20/2013
Current Effective Date:  10/10/2022

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

In April 2011, the NovoTTF-100A™ System (Novocure; assigned the generic name of TTF) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. The FDA approved label reads as follows: "The NovoTTF-100A System is intended as a treatment for adult patients (22 years of age or older) with confirmed GBM, following confirmed recurrence in an upper region of the brain (supratentorial) after receiving chemotherapy. The device is intended to be used as a stand-alone treatment and is intended as an alternative to standard medical therapy for recurrent GBM after surgical and radiation options have been exhausted."

In September 2014, FDA approved Novocure's request for a product name change from NovoTTF-110A System to Optune®.

In October 2015, FDA expanded the indication for Optune in combination with temozolomide to include newly diagnosed GBM. The device was granted priority review status in May 2015 because there was no legally marketed alternative device available for the treatment of newly diagnosed GBM, a life-threatening condition. In July 2016, a smaller, lighter version of the Optune device, called the Optune System (NovoTTF-200A System), received FDA approval.

The FDA-approved label for newly diagnosed GBM reads as follows: "This device is indicated as treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy."

In May 2019, the FDA approved a modified version of the Optune System (NovoTTF-100A System), which is now called the Optune Lua™ System (NovoTTF™-100L System), for "treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy. The indication was modified from that granted for the Humanitarian Device Exemption designation to more clearly identify the patient population the device is intended to treat and in which the safety and probable benefit of the device is supported by the available clinical data."
In September 2021, the FDA granted breakthrough designation to the NovoTTF-200T System for use together with atezolizumab and bevacizumab for the first-line treatment of patients with unresectable or metastatic liver cancer.

To date, all of the existing tumor treating fields products fall under the brand name Optune. In March 2020, the manufacturer of Optune products announced a plan to include a suffix after the brand name for newly approved indications to further delineate specific indications for individual products (eg, Optune Lua).

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Tumor treating fields (TTF) therapy is a noninvasive technology intended to treat glioblastoma and malignant pleural mesothelioma on an outpatient basis and at home using electrical fields. Glioblastoma multiforme (GBM) is the most common and deadly malignant brain tumor. It has a very poor prognosis and is associated with low quality of life during treatment. Malignant pleural mesothelioma is an aggressive tumor with few treatment options that is associated with significant morbidity and mortality.

**Summary of Evidence**

For individuals who have newly diagnosed GBM on maintenance therapy after initial treatment who receive TTF therapy as an adjunct to standard maintenance therapy, the evidence includes a randomized controlled trial (RCT) and a systematic review. Relevant outcomes include overall survival (OS), disease-specific survival, symptoms, functional outcomes, quality of life, and treatment-related morbidity. The EF-14 trial found a significant increase of 2.7 months in progression-free survival (PFS) and an increase of 4.9 months in OS with the addition of TTF therapy to standard maintenance therapy (ie, temozolomide) in patients with newly diagnosed GBM. Although patients were not blinded to treatment assignment, PFS was assessed by blinded evaluators, and the placebo effects on the objective measure of OS are expected to be minimal. In a
Tumor Treating Fields Therapy

Policy # 00391
Original Effective Date: 11/20/2013
Current Effective Date: 10/10/2022

Systematic review that included the EF-14 trial along with other observational studies, the pooled median OS and PFS in newly diagnosed patients who received TTF therapy was 21.7 months and 7.2 months, respectively. This technology represents a clinically significant option in the treatment of patients with GBM, for whom options are limited. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have progressive or recurrent GBM who receive TTF therapy as an adjunct or alternative to standard medical therapy, the evidence includes an RCT, nonrandomized comparative studies, and a systematic review of these data. Relevant outcomes are OS, disease-specific survival, quality of life, and treatment-related morbidity. The single RCT evaluating TTF therapy for recurrent GBM did not show superiority of TTF therapy for the primary outcome (OS) compared with physicians' choice chemotherapy. Because no serious adverse effects have been identified with TTF therapy, this raises the possibility that treatment with TTF might reduce the toxicity associated with treatment for recurrent GBM. A reduction in chemotherapy-associated toxicity without loss of efficacy would be considered a net health benefit. However, this RCT is not sufficient to permit conclusions on the efficacy of the device. Because the trial was not designed as a noninferiority trial, no inferences of noninferiority compared with chemotherapy can be made. Also, quality of life assessment was measured in an insufficient number of patients to reach firm conclusions on differences in quality of life between TTF therapy and medical treatment. The highest quality study of TTF combined with medical treatment for recurrent GBM is a post hoc analysis of the EF-14 trial. In a systematic review that included the RCT and post hoc analysis of the EF-14 trial, along with other observational studies, the pooled median OS and PFS in patients with recurrent GBM who received TTF therapy was 10.3 months and 5.7 months, respectively. A high-quality, prospective RCT is needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have unresectable, locally advanced or metastatic, MPM who receive TTF therapy as an adjunct to standard maintenance therapy, the evidence includes a single-arm prospective study conducted in 80 patients and a retrospective study of 5 US patients. Relevant outcomes include OS, disease-specific survival, symptoms, functional outcomes, quality of life, and treatment-related morbidity. In patients who received TTF therapy in combination with pemetrexed and cisplatin or carboplatin, median OS was 18.2 months (95% CI, 12.1 to 25.8 months). Because there was no comparison group, it is not possible to make conclusions about the effectiveness of the intervention compared to medical therapy alone. The retrospective study is the first publication of...
real-world implementation of TTF for MPM. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Supplemental Information**

**Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

**2016 Input**

In response to requests, input was received from 3 physician specialty societies (1 of which provided 6 responses and 2 of which provided 1 response each) and 1 academic medical center (total of 9 individual responses) while this policy was under review in 2016. There was majority support, but not consensus, for the use of tumor treatment fields therapy as an adjunct to maintenance treatment following initial therapy for glioblastoma multiforme. There was mixed support for the use of tumor treatment fields as an alternative to chemotherapy in advanced or recurrent glioblastoma multiforme.

**Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

**National Comprehensive Cancer Network**

National Comprehensive Cancer Network guidelines on central nervous system cancers (v.2.2021) include recommendations for the treatment of glioblastoma (see Table 1). For the initial treatment of patients with glioblastoma with good performance status and either methylated or unmethylated or indeterminate O6-methylguanine-DNA methyltransferase promoter status, treatment with standard brain radiotherapy plus concurrent temozolomide and adjuvant temozolomide plus alternating electric field therapy is a category 1 recommendation. Alternating electric currents
therapy is only an option for patients with supratentorial disease. Consideration of alternating electric field therapy for recurrent glioblastoma is a category 2B recommendation.

Table 1. Guidelines for Adjuvant Treatment of Glioblastoma, by Age and Performance Status

<table>
<thead>
<tr>
<th>Age, y</th>
<th>KPS Score, %</th>
<th>Treatment Options</th>
<th>Category</th>
</tr>
</thead>
</table>
| ≤70    | ≥60          | • Standard RT plus concurrent and adjuvant temozolomide plus TTF  
• Standard RT plus concurrent and adjuvant temozolomide | 1        |
| ≤70    | <60          | • Hypofractionated RT with/without concurrent or adjuvant temozolomide  
• Temozolomide  
• Palliative/best supportive care | 2A       |
| >70    | ≥60          | • Hypofractionated RT plus concurrent and adjuvant temozolomide  
• Standard RT plus concurrent and adjuvant temozolomide plus TTF | 1        |
| >70    | <60          | • Hypofractionated brain RT alone  
• Temozolomide alone  
• Palliative/best supportive care | 2A       |

KPS: Karnofsky Performance Status; RT: radiotherapy; TTF: tumor treating fields.

*a Hypofractionated RT plus concurrent and adjuvant temozolomide is only a Category 1 recommendation in patients with methylated O\(^6\)-methylguanine-DNA methyltransferase promotor status

The National Comprehensive Cancer Network guidelines on malignant pleural mesothelioma (v.1.2022) do not address tumor treating fields as a treatment option for malignant pleural mesothelioma.

**U.S. Preventive Services Task Force Recommendations**

Not applicable.
Tumor Treating Fields Therapy

Policy # 00391
Original Effective Date: 11/20/2013
Current Effective Date: 10/10/2022

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 2. Of particular note are the phase 3 trials evaluating TTF therapy in non-small-cell lung cancer and pancreatic cancer. Tumor treating fields therapy is an active area of research for mechanisms underlying its effects on cancer cells.

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03940196a</td>
<td>ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study</td>
<td>540</td>
<td>Sep 2023</td>
</tr>
<tr>
<td></td>
<td>of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paclitaxel for the Treatment of Platinum-resistant Ovarian Cancer (PROC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02831959a</td>
<td>Pivotal, Open-label, Randomized Study of Radiosurgery With or Without</td>
<td>270</td>
<td>Sep 2022</td>
</tr>
<tr>
<td></td>
<td>Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases From</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-small Cell Lung Cancer (NSCLC) (METIS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02973789a</td>
<td>LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields</td>
<td>534</td>
<td>Sep 2023</td>
</tr>
<tr>
<td></td>
<td>(TTFields) Concurrent With Standard of Care Therapies for Treatment of</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03377491a</td>
<td>EF-27 Pivotal, Randomized, Open-label Study of Tumor Treating Fields</td>
<td>556</td>
<td>Sep 2024</td>
</tr>
<tr>
<td></td>
<td>(TTFields, 150kHz) Concomitant With Gemcitabine and</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tumor Treating Fields Therapy

Policy # 00391
Original Effective Date: 11/20/2013
Current Effective Date: 10/10/2022

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02663271a</td>
<td>A Phase 2, Multi-center, Single Arm, Histologically Controlled Study Testing the Combination of TTFields and Pulsed Bevacizumab Treatment in Patients With Bevacizumab-refractory Recurrent Glioblastoma</td>
<td>18</td>
<td>Mar 2022</td>
</tr>
<tr>
<td>NCT01971281a</td>
<td>A Phase II Study of TTFields (150 kHz) Concomitant With Gemcitabine and TTFields Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma</td>
<td>40</td>
<td>Dec 2017 (unknown)</td>
</tr>
<tr>
<td>NCT01894061a</td>
<td>A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma</td>
<td>40</td>
<td>Jul 2019 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

a Denotes industry-sponsored or cosponsored trial.

References
Tumor Treating Fields Therapy

Policy #  00391
Original Effective Date:  11/20/2013
Current Effective Date:  10/10/2022


Tumor Treating Fields Therapy

Policy #  00391
Original Effective Date:  11/20/2013
Current Effective Date:  10/10/2022


Policy History
Original Effective Date:  11/20/2013
Current Effective Date:  10/10/2022
11/07/2013   Medical Policy Committee review
11/06/2014   Medical Policy Committee review

©2022 Blue Cross and Blue Shield of Louisiana
Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Tumor Treating Fields Therapy

Policy #  00391
Original Effective Date:  11/20/2013
Current Effective Date:  10/10/2022

08/03/2015  Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
10/29/2015  Medical Policy Committee review
11/16/2015  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/09/2018  Medical Policy Committee review
08/15/2018  Medical Policy Implementation Committee approval. This policy was retired on 3/16/2016 and has been returned to active status. Title changed from “Tumor-Treatment Fields Therapy for Glioblastoma” to “Tumor Treating Fields Therapy”. Added that an initial 6 months of TTF therapy will be eligible for coverage when criteria are met to treat GBM as an adjunct to standard maintenance therapy with temozolomide in patients with newly diagnosed GBM following initial treatment with surgery, radiotherapy, and/or chemotherapy. Added that continuation of TTF therapy may be eligible for coverage with criteria.
09/05/2019  Medical Policy Committee review
09/11/2019  Medical Policy Implementation Committee approval. Malignant pleural mesothelioma added to list of conditions for which the therapy is considered investigational. Revised investigational statement to cover when ALL criteria are not met.
09/03/2020  Medical Policy Committee review
09/09/2020  Medical Policy Implementation Committee approval. Coverage eligibility unchanged. FDA section updated to include information differentiating between Optune and Optune Lua products.
09/02/2021  Medical Policy Committee review
09/08/2021  Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
09/01/2022  Medical Policy Committee review
09/14/2022  Medical Policy Implementation Committee approval. maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy” to the criteria bullet for supratentorial tumor. Edited criteria for continuation of tumor treating fields to include individuals being willing to use
Optune for at least 18 hours a day and has attempted to use it at least 75% of the time for 18 hours per day.

Next Scheduled Review Date: 09/2023

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>No codes</td>
</tr>
<tr>
<td>HCPCS</td>
<td>A4555, E0766</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>C71.0-C71.9</td>
</tr>
</tbody>
</table>
Tumor Treating Fields Therapy

Policy # 00391
Original Effective Date: 11/20/2013
Current Effective Date: 10/10/2022

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;

B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.
Tumor Treating Fields Therapy

Policy # 00391
Original Effective Date: 11/20/2013
Current Effective Date: 10/10/2022

† Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.